HighVista Strategies’s Aegerion Pharmaceuticals AEGR Stock Holding History

HighVista Strategies’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-253,010	Closed	-$936K	–	217
2016 Q1	$936K	Hold	253,010	–	–	0.18%	149
2015 Q4	$2.56M	Sell	253,010 -12,100	-5%	-$146K	0.47%	35
2015 Q3	$3.6M	Hold	265,110	–	–	0.68%	66
2015 Q2	$5.03M	Hold	265,110	–	–	0.86%	36
2015 Q1	$6.94M	Buy	+265,110	New	+$6.75M	1.11%	19

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HighVista Strategies's AEGR Position: Q2 2016 in Review

HighVista Strategies sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 253,010 shares — an estimated $936K sold.

HighVista Strategies first reported a position in AEGR in Q1 2015 and held it in 5 quarters. The position peaked at $6.94M in Q1 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

HighVista Strategies reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
HighVista Strategies sold 253,010 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $936K.
HighVista Strategies first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 5 quarters.
HighVista Strategies's Aegerion Pharmaceuticals position peaked at $6.94M in Q1 2015.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on HighVista Strategies's 13F filing for Q2 2016, filed 15 Aug 2016.